Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning, everyone, and welcome to the Herantis Pharma webcast covering our results and key developments for the first half of 2026. Thank you for joining us today. My name is Antti Vuolanto. I am the CEO of Herantis Pharma, joined today by CFO Tone Kvåle and CMO Juha Savola. During the presentation, we will provide an update on our progress during the first half of the year, including the latest developments with HER-096 and our plans going forward. We will also have a short discussion with our new Chief Medical Officer, Juha Savola, who recently joined us. As we prepare for the next stage of HER-096 clinical development. Following the presentation, we will have a Q&A session. You can submit questions at any time through the webcast dashboard. A recording of today's webcast will also be made available after the live broadcast. Before we get started, please take a moment to note the customary disclaimer shown on the screen. And with that, let's begin. At Herantis Pharma, we are a clinical-stage public company developing disease-modifying therapies for Parkinson's disease. And we are listed on the Nasdaq First North Growth Market Finland. Our lead asset, HER-096, is now ready to move forward to a Phase 2 efficacy trial. Based on the very encouraging Phase 1 data set. So we have evaluated HER-096 in Parkinson's patients, and in healthy volunteers, we have demonstrated a favorable safety and tolerability profile. We have demonstrated efficient brain penetration. And we also have a strong biomarker data set that suggests a biological response in Parkinson's patients, and the response is consistent with the proposed mechanism of action. In addition to that, we are in a very special situation, as we also have earlier biological validation with CDNF, cerebral dopamine neurotrophic factor, and related biology in previous clinical and translational studies. CDNF is a naturally occurring protein that protects and restores the function of dopaminergic neurons. And now, with HER-096, we can bring the same activity to the brain using very convenient subcutaneous administration. So we believe that we are in a very strong position when we now go towards the Phase 2 efficacy trials. If I shortly summarize the different aspects, they provide a very strong foundation for the Phase 2 development. First of all, we have significant unmet clinical need in Parkinson's disease. Currently, patients can receive symptomatic treatment addressing motor symptoms at the early stage of the disease or right after the diagnosis. However, no disease-modifying drugs affecting the disease progression exist as of today, so there is a large and growing market with high unmet clinical need. I will actually discuss that in further detail shortly. The approach that we have with HER-096, the mechanism of action derived from CDNF, is a very broad mechanism, addressing actually the very core disease biology. And this really puts us in a very specific position, considering the other potentially disease-modifying therapies in development. I will also discuss a little bit more about the competition or the situation in the disease-modifying therapy space in Parkinson's disease. As already mentioned, the Phase 1 data and the preceding preclinical data with HER-096 is very encouraging and very strong compared to the peers. Considering the data set that leads to Phase 2, we do have a very strong rationale for Phase 2. The specific design that we have created, and are still finalizing regarding clinical, biomarker, and translational evidence, provides a strong rationale that we will then test in Phase 2 to demonstrate patient benefit and efficacy. I already mentioned the unmet clinical need. So, the current therapies are symptomatic therapies that only treat the motor symptoms, not the disease itself. And there are very severe non-motor symptoms that cannot be treated today, even though at the early stage of the disease, many patients can have efficient symptomatic benefit from the current treatments. There are also a number of patients who either don't get the symptomatic benefit, or they may have significant side effects. And what is especially important to know is that the effectiveness of the current treatments declines over time as the underlying disease progresses. So all the patients who are diagnosed with Parkinson's disease know that there will be a day when the current treatments are not sufficiently supporting their quality of life, and it will be compromised at some point in time. And we want to make a change here. And this is, of course, associated with a huge opportunity. Huge potential considering the market size. So currently there are ten or maybe 12 million patients suffering from Parkinson's disease globally. It is expected to more than double by the year 2050, when approximately 25 million patients might be suffering from Parkinson's disease. And today, the total economic burden of Parkinson's globally exceeds 250 billion USD. So we are talking about a huge unmet clinical need and a huge market. The therapeutic market currently is approximately 6 billion or 7 billion USD a year. With these symptomatic treatments, we estimate that. And there are many estimates that say that it will at least double when the first disease-modifying treatments will enter the market. And of course, our ambition is to be there. And there is very strong pharma interest in disease-modifying therapies in Parkinson's disease, for example, Roche, Eli Lilly, AbbVie, and MSD. All of these large players have publicly stated that they are very interested in this space. So the opportunity is huge. A short update about the current situation regarding disease-modifying therapies: HER-096 has a very strong position based on its broad mechanism, which addresses core biology and offers the potential to protect and even restore neuronal function. So despite the huge unmet clinical need and the huge market, the treatment pipeline remains rather limited. The treatment pipeline remains rather limited. Many or most of the competing programs focus on relatively narrow mechanisms, including immunotherapies against alpha-synuclein, protein aggregates, kinase inhibition, or lysosomal or GBA pathways. And also, there are cell replacement therapies looking at Phase 3. There is one compound from Roche, which is an alpha-synuclein immunotherapy, going into Phase 3. It hasn't yet started, but it will be initiated rather soon. And in Phase 2, there has actually been some news during the summer time. So there have been these genetic lysosomal targets both from Biogen, Denali and then a Portuguese company called BIAL, which both have reported negative outcomes in the summertime. Both of these companies have announced that they will discontinue development, while cell therapies have also been discussed in Finnish newspapers. And that might be a promising technology. However, there are many challenges regarding the practicalities related to cell therapies, as cell therapies mean that you. You have. You grow neurons outside of the human body. Then you implant them into the anatomical site with a surgery. With a rather complicated surgery and then with the hope that the new neurons can be active at the site. Neurons can be active at the site and there are some promising results. However, it is most likely not very suitable to treat millions of Parkinson's patients or 250,000 newly diagnosed cases in the US annually. So it can be a limited niche product, but it definitely cannot saturate the market. So based on this, when HER-096 continues to Phase 2 development, we are in a very good and very strong position regarding disease modification in Parkinson's disease. So we are planning for the Phase 2 efficacy trial in early-stage Parkinson's disease patients. This Phase 2 efficacy proof-of-concept study aims to show improvement in motor symptoms using continuous objective monitoring of motor symptoms with sensitive digital devices, and with that, we have partnered with Indivi AG, who provided the same platform for Biogen's trial with approximately 600 participants. We will also have clinical symptom assessments as a standard practice and different brain imaging modalities as a measure of disease modification. And of course, we will exploit the great biomarker data that we have got from Phase 1b. We will also select fluid biomarkers to complement the data package. The Phase 2 trial itself will be a randomized, placebo-controlled, double-blinded trial with two different parts. The first part will be a nine-month, placebo-controlled part. And then the next six months will be open-label. So all the participants will receive HER-096 treatment, with approximately 100 early-stage Parkinson's disease patients. They will receive two subcutaneous 300mg injections per week or placebo in the first part of the trial. And the preparations for this European study are underway. And we already have very advanced discussions with a number of clinical sites across different countries, including the Nordics, Central Europe, and Southern Europe, to have a sufficient number of sites to recruit the patients within hopefully 12 months. So we expect to submit the clinical trial application by the end of this year. We plan to have the first patient in the protocol during the first half of next year and the interim efficacy data readout early 2029, followed shortly after by the full data set of Phase 2. As announced earlier in the spring. We also had a discussion with the FDA about our plans, and their feedback supports the planned Phase 2 development strategy. They. They considered the trial design appropriate for Phase 2. They did not raise any concerns about the data package that we discussed with them. So basically, the feedback supports submitting an IND. So potentially we could also obtain regulatory approval from the FDA to conduct the phase two trial. So let's go to the business highlights of the first half of 2026. In January, we reported positive biomarker data that showed a very clear biological response to HER-096 treatment in people living with Parkinson's disease. And the biological response was very much aligned with the expectations regarding the proposed mechanism of action. So improvements in proteostasis and mitochondrial function capacity. In February, we completed a directed share issue. We raised €4.2 million in that transaction. Further, in February, we also announced that the consortium led by Herantis Pharma was selected to receive an €8 million grant to support the Phase 2 trial of HER-096. And the acronym of that EU project is HERMOD. So it covers part of the planned Phase 2 trial that we are going to initiate later. In March. Our Chief Scientific Officer, Henri Huttunen, delivered an oral presentation at the ADPD 2026 Congress presenting the Phase 1b data. That was also a very important scientific milestone for the company. In May, we announced a collaboration with Indivi AG for a digital biomarker platform for the Phase 2 trial. Of course, the aim is to detect early treatment-related changes. In the phase two trial in May. Further on, we received the positive feedback from the FDA. From FDA that I already discussed in May. Further, we announced that we appointed the clinical CRO to support our Phase 2 preparations and, eventually, the conduct of the trial. And in June, we announced the appointment of Dr. Juha Savola as our Chief Medical Officer. He brings more than 25 years of global experience in drug development. Let's discuss this topic later when I have a chat with Juha. But let's dive now into the financing figures. So CFO Tone Kvåle, please take the lead here.
Yeah. Thank you for the introduction. The cost base, as you can see, remained flat compared to the same period last year. During the first half, we have spent our resources on the following core projects. We are now preparing for the Phase 2 clinical trial. We are continuing development and validation of the biomarkers. In addition, as Antti mentioned, we raised funds in February, so there was cost set aside for that. And of course, we are focusing a lot on investigation and partnering activities. So that is also a part of the resource spend. Next slide. As you have heard today, we were selected for an 8 million Horizon Europe grant. That is really positive. That is a form of non-dilutive funding which is important for us, and our cash position by the end of June ended at 3.5 million. The balance sheet also consisted of long-term debt that increased compared to the same period last year due to more funding from the Michael J. Fox Foundation. Fox and Parkinson's UK. As you remember, they funded the full Phase 1b trial. Equity stood at -0.7 million euros by the end of June. We mentioned the successful fundraising. And then of course, in addition, just to say that we need to have more capital to launch the Phase 2 clinical trial. And we are actively exploring different options, for instance, development partnerships, equity financing, and also more non-dilutive funding.
Thank you. Next, we will have a short discussion with Juha, our Chief Medical Officer. Juha brings extensive experience from the pharmaceutical industry with a strong track record in clinical drug development and special expertise in neurology. He joins, of course, Herantis Pharma. Now at a very important moment as we prepare to advance HER-096 into Phase 2 development. So, Juha, welcome to Herantis Pharma. It is, of course, great to have you with us. And here, before we actually dive into Herantis Pharma HER-096, could you briefly tell our audience about your background and maybe highlight the experience that you believe has best prepared you for the role of Chief Medical Officer at Herantis Pharma.
Sure. Thanks, Antti, and thanks everybody. It is good to be here. An exciting moment for Herantis Pharma, and I am really proud to be part of making things move forward. I have worked, as you said, quite many years in the field, many of those being responsible for leading clinical development in neurology and some other therapeutic areas. But Parkinson's disease has been the field where I have done actually most of the clinical research. I actually joined this from retirement. Before stepping out from pharmaceutical drug development, I worked for five years in my last role in Philadelphia, USA, at Spark Therapeutics, which is a gene therapy company. We had developed the very first gene therapy for the treatment of a genetic blindness. In that role, we started a therapy for the treatment of another rare disease with neurological consequences. That is Huntington's disease. We were thinking about and planning the advancement of a Parkinson's disease compound. So I would say that these years in business have kept me very excited about Parkinson's disease and very committed to finding better solutions for patients. All these years have led me to fine-tune what might be the most optimal way of designing a study to address those unmet needs in my roles. Working especially with rare diseases, I learned to appreciate the value of a single subject in the study. And that, I think, is important. Thinking on this, we must be prudent. We cannot recruit many patients and simply rely on large volumes of data. Providing the future for the program development. We need to be smart. We need to make every patient count in the study, and that will be the best feedback we can give to the patients and scientific community. So yes, I think my background in the field of neurological disease across different modalities, and the real opportunity to provide something meaningful for patients, is making my work very exciting.
That is very good. Quite an impressive background. What in HER-096 and Herantis Pharma has convinced you to join? You said that you had retired, but then you wanted to come back to an operational role. So what is that compelling thing that you see in HER-096? Maybe also compared to other approaches that are currently being evaluated in Parkinson's disease?
Well, there are two things, if not three even; first of all, the very concept of HER-096, which is attractive for me, is that it is not, as you pointed out, a single mechanism of action. It is a targeted mechanism of action, but it is playing across the pathology of Parkinson's disease, which is important. And I think this is important scientifically in comparison to many very focused, laser-focused biological approaches. And so, that biological non-specificity is important for a disease like Parkinson's disease therapy. What was exceptional when I listened to and watched your data readout, and when you had your Phase 1 data out, I was impressed that in Phase 1, you actually had a signal that this experimental drug is biologically active. And everything I saw at that moment and later on, as I have had access to the books, is building on that story that we did not find any surprises there. We actually got a signal that the hypothesis built on preclinical animal studies appears to be valid for humans. And that is a jump start. And that made me excited. And of course, this motivation is exceptional. And shortly after speaking with you and other colleagues in this spirit, I felt it was spot on in this company.
Very good. And that leads to the next item that I had in mind. So you have now spent the first two months at Herantis Pharma with the team. So, what has most impressed you about this company or our great team; I would say the great team. But maybe you.
I cannot deny that. As I said, this is showing. It is living every moment; I see it and I feel it when I am with Herantis Pharma, seeing the people, and everybody is engaged. Everybody wants to make an impact on the lives of Parkinson's patients and their families. Everyone. Everybody knows what we are doing and why we are doing it, and the level of engagement and commitment is very tangible. So it is, and there is a good humor in the company. And it's a perfect place to work.
Well, that sounds very good. Of course, from the perspective of the CEO. Well, you have seen the full body of evidence that we have built now within the first two months of your engagement with Herantis Pharma. What is in a way the most encouraging aspect, given you mentioned the broad mechanism of action? But if you consider the data set that we have, what is convincing you that yes, we are going in the right direction. Considering the long track of evidence that we have built from the CDNF preclinical to HER-096 Phase 1 data. So.
Well, let's go to the very basic mechanism of action. The evidence here has been built around CDNF first and then later on HER-096, which is very compelling in the field of any modality. I am aware of competing products. There is an opportunity for neurorestorative treatment, meaning this drug might make cells behave better and they might catch up and they might finally be something which is doing more than simply providing a reduction in the rate of clinical progression. And that would be fantastic for these patients. I can see a glimmer of hope coming from these cell culture studies and our animal studies. So that was the first thing, which was my attraction. When I was going through the documentation, I had access to the preclinical package that has been well thought out, well planned, and well executed. Impressive. And then on top of that, as I mentioned, our human data is building up on that story. And it makes me very hopeful that we are able to create something which stands out in the crowd. And this, what we are doing, really will make an impact for patients.
Right? And now as we prepare for Phase 2, what do you see as the most important elements of the study design so that we can maximize the chances of success, which is, of course, very critical. Phase 2 is the critical step towards commercialization.
It is a critical step for any company. The program is still early. We need to have a study that tells us if we need to stop this treatment. The concept, and not invest anything in that, because it would be likely wasted money; or we need to have evidence and signal that there is continued reason in believing in the compound. And this is a very solid stepping stone for us to move forward. The design has to be creative, the design has to be smart, and smart in a way that we are able, as I said, to use every subject in the study to build up an understanding of whether this drug is doing what we are expecting it to do and what we hope it will be doing. Finding the right elements for measuring the biological therapeutic benefit is important. The biological therapeutic benefit is important. For that, I think your choice of building up initial efficacy demonstration on smartphone data is smart, obviously. And because it is so much more sensitive to detecting these subtle movement disorder symptom severities, it will also be more sensitive than traditional measures in detecting if there is potential treatment benefit. So I believe that the compound is safe. That is based on Phase 1 data and is probably not a question anymore. The question now is what handle we can get on efficacy. Parkinson's disease is not easy from that perspective. We are so much dependent on the Parkinson's subject behavior and what we can measure and how we can measure and quantify that disturbance. And I think that is the tricky part in early patient populations.
Yes. And a bit broader view. Looking ahead. So how would you define success for HER-096, considering the Parkinson's patients and maybe also Herantis Pharma considering Phase 2 and beyond? So, what can you foresee here?
What I can foresee is interesting. There is a potential that we are able to demonstrate therapeutic benefit in this Phase 2 study. We do everything we can to build a protocol where we are maximizing the probability of picking up the signal of therapeutic potential, and without that, there is no path forward with this component. It is even our call and our ethical duty to the patient community out there to be honest with the data and see if there is a reason to move forward or not. We will continue developing. If we are picking up the signal, this study will be a sufficient stepping stone in developing this drug forward, and we should be ready for confirmatory Phase 3 studies where we are truly demonstrating that it is benefiting the patients, and their observations on how the disease is impacting their daily activities can be documented and demonstrated. And then with those data, the product can be taken to global markets. Obviously, that confirmatory Phase 3 program is beyond our reach. It does require a global player. For Herantis Pharma, these data are critical for licensing partner identification and for the patient community. It is an important additional flicker of hope that there is something that will come up to benefit them. You mentioned that there are many activities occurring in the Parkinson's disease pipeline. That is good for patients. That is so important because there have been so many disappointing years. Nothing truly significant has been introduced over a couple of decades in Parkinson's disease. And that is sad for anybody who is living with the disease.
Yes. All right. With these words, let's continue with the Q&A session.
Yes. And we have received many questions, but there is still room for more. So, what is the rationale for pursuing an FDA submission alongside the European CTA during Phase 2?
That is, of course, a very good question. We are planning a European study. However, having the FDA's blessing would act as an external validation for the program. Do you have any other view from the big pharma standpoint, as you come from that background?
For them, it is important that the FDA has input in this. These are the pharma partners whom we would be approaching. We would be approaching. They need U.S. Clinical research conducted as well. And for that, we have already completed six months of preparation work so that when they receive our data, we can proceed. I am saying we will probably have a joint meeting with the FDA. And then Phase 3 plans can be nailed down and the program can move forward. It is a huge shortening of the white space in development. So it will be paid back to the licensing partner. And of course, market time will be much earlier.
Very good.
Next, what are the key milestones investors should expect over the next 12 months?
Yeah. Of course. As we already mentioned during the webcast, we are now preparing for the Phase 2. And there are, of course, important milestones: submitting the clinical trial application by the end of the year and starting the actual clinical trial patient treatments in the first half of next year. And of course, before that, we need to secure the resourcing for the Phase 2 trial, as you mentioned, we are in discussions with pharma companies related to partnering. We are in discussions with investors and also non-dilutive financing. And of course, we are very confident that the timelines that we have communicated will hold. They will hold. And. And we have a very good kickstart for the Phase 2 program.
Yeah. Good. In previous communication, you have referred to the upcoming Phase 2a study and it is now being called a Phase 2 study. What has changed, and do you need more money for this?
Yes. This is a very good question. Again. It is a tiny, tiny letter, an A, but it might have a certain meaning. And of course, claiming Phase 2a or Phase 2 is not a regulatory label. It is more like the company communication label. And this is actually one thing that you brought with you, your big pharma view on how we should define items. So maybe you could provide the rationale why you believe that phase two is the right wording and what it means for the phase two trial? Phase three?
Yes. To me, it was clear after seeing our Phase 1b data, which provided evidence of proof of mechanism. Therefore, I do not need to redo that in many patients; I want to design a study and commit to conducting a trial that is ready to build our understanding of whether or not we should continue into a confirmatory study. And with these numbers of patients we are considering, we should be able to support progressing into a pivotal program.
And I can also confirm that no extra resources or money are required. So it is maybe a branding and labeling item, not as such a design item for the trial. Yeah.
Can you update us on the status of all your other indications beyond Parkinson's disease? Are you doing any preclinical studies on those programs?
That is a very good question. And based, of course, on what we have disclosed earlier, we have almost fully concentrated on Parkinson's disease and we have not divided our resources into other indications too heavily. However, I can mention that, yes, we have, for example, filed a patent application in a non-CNS indication earlier this year. We have not disclosed what that indication is. And, of course, there are no decisions to invest in that program. Our ambition is currently to secure that. We can continue to Phase 2 development. And then once the resources are there, we, of course, would like to invest more on the other indications. Of course, the mechanism of action must support expanding beyond Parkinson's disease. And that is, of course, also the ambition of the company at the right point in time going forward.
Referring to the Phase 2 trial, the upcoming one. Can you define early stage with some symptoms and can cities in Finland, such as those in Northern Finland, also be involved in clinical tests? How do we apply for the testing group?
Yes. Maybe you could comment on how this is practical.
Yes. Thank you. It is a good question. We use only clinical assessment to define if somebody is early with their disease progression or more advanced. That is well established in clinical research of Parkinson's disease. We are looking for subjects who were not diagnosed a long time ago, but rather subjects who were quite recently diagnosed. That is one way of identifying the right patient population. And that is important so that we do not have a very diverse group of people with different stages of disease. Now, the investigators, sites, and geographical access we are looking for are primarily driven by identifying doctors who are experts in this field of clinical research. And that is not really putting a pin on a map and saying we need to do it here. We do it there. We select locations based on the presence of experts we need. But we, as a sponsor, have many mechanisms in our repertoire that we can use to facilitate participation if somebody lives in the northern part of Finland. And our investigators are in the southern part of Finland. Then how do we facilitate that back and forth movement. But it will be a logistical challenge in a country like Finland, which is a very long country. So it is going to be a challenge when it comes to geography.
And maybe I will continue a bit. So in practice, we are now planning to submit a clinical trial application. And once we get approval, then we can activate the patient recruitment activities. Herantis Pharma as a sponsor does not recruit the patients directly. It will be the clinical sites who will actually recruit the patients. And of course, we as a sponsor will also publish guides on how to conduct the investigators and how to get involved in the trial, but this will be. We will inform the patient community as soon as we have all the required information available.
Very important addition. Thank you.
Yeah. What is the expected cost for the Phase 2 study and what additional financing is needed until its completion and results will be known?
Yes. As already disclosed, the trial cost lands somewhere around €20 million and the total financing need of the company is around €30 to €35 million, from which we have secured that €8 million non-dilutive EU grant. And a reminder that we do have a commitment from the EIC fund for equity investments. And based on the term sheet that we signed in 2023, they can have an option for up to one third of equity. Financing. If we go through that route. And of course, once we go a bit further with the resourcing of the Phase 2 trial, we will definitely inform the market in due course about any development on that side.
Good morning. Thank you for the presentation and congratulations on the progress. Developments so far this year have been encouraging. Can you share how discussions have evolved since the start of the year? Would you prefer the outcome to be to secure a partner before Phase 2 starts, or will you retain greater ownership through the proof-of-concept readout?
A very good question. And that is of course the thing that the company and the board of directors are continuously assessing as to what makes sense. What are the options? As we have quite openly communicated, we have had very active discussions with several, both global and regional partners over the years. And as already mentioned, we will inform the market in due course when there are any developments. But of course, the question is correct that we need to consider the ownership retainment related to Phase 2 and what actually builds the biggest value for our shareholders. And that is, of course, something that we want to ensure: that in the longer term, our shareholders get the best value, which would be aligned with the value of our HER-096 and the value for the patient. So, everything is in the same basket.
Should we expect a material step up in R&D and cash burn through the next half year and also into 2027 as manufacturing, regulatory and site activities accelerate.
Yes, definitely. That is a valid point. So when we approach and start the Phase 2 trial, of course the R&D expenses will increase. But as already mentioned during the presentation, to activate the Phase 2 trial, we need to secure more resources for that. So. So just follow the news flow, and that will explain the next steps and how we ramp up with the Phase 2 execution.
Yeah. With the discontinuation of the Biogen program in early-stage Parkinson's disease. From your perspective, what are the key differences between that program and HER-096. Does the program failure, if anything, reinforce your approach based on a biomarker-supported mechanism and a more sensitive digital primary endpoint.
Yeah. First of all, the Biogen Denali mechanism was very different from what we have at Herantis Pharma. So their approach was targeting a specific target. Target kinase target, which is expressed actually in a fraction of patients. But in this trial, they wanted to treat idiopathic or all-comers in a way. They showed in the trial that on that broad patient population, it was not efficacious with the study setup that they built. And considering our mechanism of action, which is very broadly addressing the core biology of Parkinson's disease, it is very different. What was the second part of the question?
Does the program failure, referring to that, if anything, reinforce our approach based on biomarker-supported mechanism and a more sensitive digital primary endpoint?
I wouldn't say that the failure itself had an impact on our plans. But of course, it means that there is less competition and we are becoming more visible across the different approaches for Parkinson's disease, disease modification. Do you have any additions here?
Um yes. I would like to emphasize even this laser-focused mechanism of action that they had, and how they selected the patient population based on publicly available information; I need to remind you that we have very little information regarding the details of the study. And interestingly, Denali wants to continue in these genetically identified subpopulations. So it is telling me that there is still something which we do not understand from the data. They might. I agree with you there. Their outcome is not informing us on our risk profile, but moving forward, it is informing us that you can implement a smartphone-based data collection in a quite substantially big Phase 2 study. So at least one technical learning, which is supporting our decision-making, is coming from that study.
And actually, using those data together with published data from Roche helps us to define the statistical power behind the selected patient population and the number of patients. So it will help us in the phase two conduct and reinforce the probability of success for us.
Yes. From your comments, if all goes to plan, what is the timeline towards a Phase 3 trial?
Yes. So basically, as I explained earlier today, we expect to have the interim efficacy readout in early 2029. And that of course would already potentially trigger discussions with regulatory authorities during 2026 or 2029 or early 2030, which would mean that we would, of course, want to initiate the pivotal Phase 3 program. Maybe within a year or even less time from the end of the phase two trial. And then of course, depending on the results, we need to, together with the regulatory authorities, discuss what is the right setup for the pivotal program, the length, and the number of patients. And it really depends on the data that we will be able to get from Phase 2. But now we do have the visibility already into the pivotal program, at least in some shape and form. Do you have any additions?
Now coming back to Big Pharma, where timelines are not always. And these so-called white spaces between phase transitions are not always so critical. It is very difficult for us to control that. They go through their committees and spend time in planning and replanning. So it is difficult for us to predict when the market is ready. But what are the timelines you just referred to? Those are achievable. Yes, they are achievable. And 2030. Immediately after that should be doable. It does require that a few of the stars align. There has to be compelling data coming from this study. There has to be a strong, committed partner, which is of course important for our decision-making, and they must have the motivation to keep going with the pace we have started.
Yes, I think that concludes the Q&A session. It is going to be a very busy second half of this year, and we look forward to updating the market about our progress. Do you have any closing remarks?
Yes. So thank you for spending the time. I hope there was a big audience that stayed for almost the full hour, which I believe is the record length for our first-half webinars. Of course, the discussion with Juha and the many questions from the audience were very relevant. We were really happy to answer these questions. I hope you all have a very nice August, a late summer, and please stay tuned for news as we move forward toward a very exciting moment for this, but also overall for the whole Parkinson's community. So thank you for watching. Thank you.



















